VR/AI Neuro System Prototype
Exclusive intellectual property license from the University of Kansas of a proprietary diagnostic tool combining artificial intelligence and virtual reality to aid in the diagnosis of neurological disorders for clinical and telemedicine use
Enables remote neurological diagnosis on a low-cost, wearable virtual reality device that can visualize eye movements in videos and interface with the doctor who is in a different location than the patient, which can lead to diagnoses more accurate, less time spent making a correct diagnosis for the doctor and reduced transport costs for the patients.
Initial focus on Parkinson’s disease with first results from a pilot study in mid-2023
TORONTO, Nov. 15, 2022 (GLOBE NEWSWIRE) — DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED), a digital diagnostics and therapeutics company focused on artificial intelligence for brain health, is pleased to announce that it has entered into an exclusive worldwide licensing agreement with KU Center for Technology Commercialization, Inc., a University of Kansas not-for-profit corporation, for developing and commercializing the intellectual property of a novel virtual reality and artificial intelligence (“VR/ AI Neuro”) for the evaluation, diagnosis and monitoring of neurodegenerative diseases, such as Parkinson’s disease.
VR/AI Neuro System Prototype
The VR/AI Neuro system complements and enhances the full-spectrum digital diagnostic brain health solutions offered by DiagnaMed, which include BRAIN AGE™ and BrainTremor™, for mental health and neurological disorders. Early and accurate diagnosis is still difficult for neurodegenerative diseases such as Parkinson’s disease. Assessments can be time-consuming, patients often have to travel to metropolitan areas or different cities to see experts, and misdiagnosis can lead to inappropriate treatment. Only a handful of assistive or remote methods exist to help physicians assess patients with suspected neurological diseases in a convenient and consistent manner. The VR/AI Neuro system aims to enable clinical and remote neurological diagnosis on a portable and inexpensive virtual reality device that can visualize eye movements in videos and interface with the physician who is in a different location from that of the patient, which can result in more accurate diagnoses, less time spent on making a correct diagnosis for the physician, and reduced transport costs for patients.
The VR/AI Neuro system has been the subject of research and co-development for some time by the University of Kansas Medical Center, Osaka University and Augusta University. It is designed to support the assessment and diagnosis of neurodegenerative diseases and to test its use in a clinical setting. Using a commercially available VR display with an infrared camera built into the lens, researchers built a 3D virtual environment designed to emulate common tasks used to assess patients, such as point fixation. , the smooth pursuit of an object or the execution of saccades. These virtual tasks are designed to elicit eye movements commonly associated with neurodegenerative diseases, such as abnormal saccades, square wave jerks, and eye tremors. The researchers then conducted experiments with 9 patients diagnosed with Parkinson’s disease and 7 healthy controls to test the potential of the VR/AI Neuro system to emulate tasks for clinical diagnosis. The researchers then applied eye-tracking algorithms and image enhancement to eye recordings made during the experiment and conducted a short follow-up study with two doctors for evaluation. The results showed that the VR/AI Neuro system interface could elicit five common types of movements usable for assessment, physicians could confirm three out of four abnormalities, and the visualizations were considered potentially useful for diagnosis. [1]
With the success of the proof-of-concept study, the next stage of development is to re-implement the tests created in the original research using the updated VR/AI Neuro system and integrate it into a clinical setting with of Parkinson’s disease patients with top-line pilot study results by mid-2023.
“We are excited to advance the development of a new virtual reality and artificial intelligence neurodiagnostic system that will aim to change the way neurodegenerative diseases are diagnosed and managed,” said Fabio Chianelli, Chairman of the Board of administration of DiagnaMed. “We are focused on developing and commercializing next-generation digital diagnostic tools for brain health in mental and neurological disorders. The VR/AI Neuro system complements our product development programs, including BRAIN AGE™ and BrainTremor™, to ensure a comprehensive suite of assessment solutions that enable healthcare providers to effectively manage their patients’ conditions.
Under the terms of the agreement, DiagnaMed has been granted exclusive worldwide development and commercialization rights to a portfolio of intellectual property from the KU Center for Technology Commercialization, Inc.
About DiagnaMed Holdings Corp.
DiagnaMed Holdings Corp. (CSE: DMED) is an artificial intelligence-driven digital diagnostics and therapeutics company focused on improving brain health for mental health and neurodegenerative disorders. The Company is developing BRAIN AGE™, an electroencephalogram (EEG)-based artificial intelligence solution to detect an individual’s brain age for clinical and home use, and BrainTremor™, a wearable device to detect Parkinson’s disease tremor and essential tremor. Learn more about DiagnaMed.com.
For more information about DiagnaMed, please contact:
Fabio Chianelli
President of the council
DiagnaMed Holdings Corp.
Tel: 416-800-2684
Email: info@diagnamed.com
Website: www.diagnamed.com
Neither the Canadian Securities Exchange nor its regulation services provider has reviewed or accepts responsibility for the adequacy or accuracy of this release.
Caution
Certain statements in this press release are forward-looking statements, including with respect to future plans and other matters. Forward-looking statements consist of statements that are not purely historical, including statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forward-looking statements such as “may”, “expect”, “estimate”, “anticipate”, “intend”, “believe”, and “continue”. or the negative thereof or similar variations. . Readers are cautioned that the assumptions used in preparing any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those anticipated due to numerous known and unknown risks, uncertainties and other factors, many of which are beyond the Company’s control, including, but without limitation, business risks, economic and capital market conditions, the ability to manage operating expenses and dependence on key personnel. These statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, expected costs and the ability to achieve objectives. Factors that could cause actual results to differ materially from those in the forward-looking statements include the continued availability of capital and financing, litigation, failure of counterparties to perform their contractual obligations, loss of employees and of key consultants and general economics, market or business conditions. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under “Risk Factors” in DiagnaMed’s final prospectus dated October 28, 2022, which is available on the company profile. company at address www.sedar.com. The forward-looking statements contained in this press release are expressly qualified by this cautionary statement. Readers are cautioned not to place undue reliance on forward-looking information. The forward-looking statements contained in this press release are made as of the date of this press release. Except as required by law, the Company disclaims any intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This press release does not constitute an offer to sell or the solicitation of an offer to buy, and does not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.
Source:
-
Orlosky, Jason et al. “Emulation of Physician Tasks in Eye-tracking Virtual Reality for Remote Diagnosis of Neurodegenerative Diseases.” IEEE Transactions on Visualization and Computer Graphics vol. 23.4 (2017): 1302-1311. doi:10.1109/TVCG.2017.2657018
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/737715b3-ff6e-4e46-b350-7548d60df582
#DiagnaMed #Holdings #Acquires #Exclusive #Rights #Virtual #Reality #Artificial #IntelligenceBased #Neurodiagnostic #System #Neurodegenerative #Diseases